Literature DB >> 29454676

OPA1: How much do we know to approach therapy?

Valentina Del Dotto1, Mario Fogazza2, Guy Lenaers3, Michela Rugolo2, Valerio Carelli4, Claudia Zanna5.   

Abstract

OPA1 is a GTPase that controls several functions, such as mitochondrial dynamics and energetics, mtDNA maintenance and cristae integrity. In the last years, there have been described other cellular pathways and mechanisms involving OPA1 directly or through its interaction. All this new information, by implementing our knowledge on OPA1 is instrumental to elucidating the pathogenic mechanisms of OPA1 mutations. Indeed, these are associated with dominant optic atrophy (DOA), one of the most common inherited optic neuropathies, and with an increasing number of heterogeneous neurodegenerative disorders. In this review, we overview all recent findings on OPA1 protein functions, on its dysfunction and related clinical phenotypes, focusing on the current therapeutic options and future perspectives to treat DOA and the other associated neurological disorders due to OPA1 mutations.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DOA therapy; Dominant optic atrophy; Mitochondria dynamics; OPA1 mutations

Mesh:

Substances:

Year:  2018        PMID: 29454676     DOI: 10.1016/j.phrs.2018.02.018

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  18 in total

Review 1.  Mitochondrial Morphofunction in Mammalian Cells.

Authors:  Elianne P Bulthuis; Merel J W Adjobo-Hermans; Peter H G M Willems; Werner J H Koopman
Journal:  Antioxid Redox Signal       Date:  2018-11-29       Impact factor: 8.401

2.  Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations.

Authors:  Serena J Aleo; Valentina Del Dotto; Mario Fogazza; Alessandra Maresca; Tiziana Lodi; Paola Goffrini; Anna Ghelli; Michela Rugolo; Valerio Carelli; Enrico Baruffini; Claudia Zanna
Journal:  Hum Mol Genet       Date:  2021-01-21       Impact factor: 6.150

3.  Optimized OPA1 Isoforms 1 and 7 Provide Therapeutic Benefit in Models of Mitochondrial Dysfunction.

Authors:  Daniel M Maloney; Naomi Chadderton; Sophia Millington-Ward; Arpad Palfi; Ciara Shortall; James J O'Byrne; Lorraine Cassidy; David Keegan; Peter Humphries; Paul Kenna; Gwyneth Jane Farrar
Journal:  Front Neurosci       Date:  2020-11-26       Impact factor: 4.677

Review 4.  Dynamic properties of mitochondria during human corticogenesis.

Authors:  Tierney Baum; Vivian Gama
Journal:  Development       Date:  2021-02-19       Impact factor: 6.868

Review 5.  Dominant Optic Atrophy (DOA): Modeling the Kaleidoscopic Roles of OPA1 in Mitochondrial Homeostasis.

Authors:  Valentina Del Dotto; Valerio Carelli
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

6.  Metabolomics hallmarks OPA1 variants correlating with their in vitro phenotype and predicting clinical severity.

Authors:  Juan Manuel Chao de la Barca; Mario Fogazza; Michela Rugolo; Stéphanie Chupin; Valentina Del Dotto; Anna Maria Ghelli; Valerio Carelli; Gilles Simard; Vincent Procaccio; Dominique Bonneau; Guy Lenaers; Pascal Reynier; Claudia Zanna
Journal:  Hum Mol Genet       Date:  2020-05-28       Impact factor: 6.150

7.  Idebenone increases chance of stabilization/recovery of visual acuity in OPA1-dominant optic atrophy.

Authors:  Martina Romagnoli; Chiara La Morgia; Michele Carbonelli; Lidia Di Vito; Giulia Amore; Corrado Zenesini; Maria Lucia Cascavilla; Piero Barboni; Valerio Carelli
Journal:  Ann Clin Transl Neurol       Date:  2020-04-03       Impact factor: 4.511

Review 8.  Cardioprotective Role of Melatonin in Acute Myocardial Infarction.

Authors:  Zhenhong Fu; Yang Jiao; Jihang Wang; Ying Zhang; Mingzhi Shen; Russel J Reiter; Qing Xi; Yundai Chen
Journal:  Front Physiol       Date:  2020-04-29       Impact factor: 4.566

9.  Loss of FZO1 gene results in changes of cell dynamics in fission yeast.

Authors:  Rongmei Yuan; Xiang Ding; Xiumei Tan; Yiling Hou
Journal:  Int J Mol Med       Date:  2020-10-12       Impact factor: 4.101

Review 10.  Therapeutic Options in Hereditary Optic Neuropathies.

Authors:  Giulia Amore; Martina Romagnoli; Michele Carbonelli; Piero Barboni; Valerio Carelli; Chiara La Morgia
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.